Viking Therapeutics Announces Results From Phase 1 Clinical Trial Of Novel Oral Thyroid Receptor Beta Agonist VK0214; Says VK0214 ‘demonstrated encouraging safety and tolerability, as well as a predictable pharmacokinetic (PK) profile’
Viking Therapeutics, Inc. (Viking) (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced results from the
